ICON (ICLR, $192.36) to buy PRA Health in $12 billion deal
On Wednesday, drug and medical device maker ICON said it agreed to buy PRA Health Sciences in a deal valued at approximately $12 billion.
Under terms of the deal, ICON will pay PRA Health Sciences shareholders $80 in cash and 0.4125 a share of Icon stock—which represents around 30% premium to PRA’s closing price Tuesday.
After the acquisition happens, ICON shareholders will own 66% of the combined entity, while PRA shareholders will own about 34%.
The combined company will be headquartered in Dublin.
ICLR's RSI Oscillator ascending out of oversold territory
The RSI Indicator for ICLR moved out of oversold territory on February 23, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 27, 2026. You may want to consider a long position or call options on ICLR as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ICLR just turned positive on February 27, 2026. Looking at past instances where ICLR's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICLR advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .
ICLR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
ICLR moved below its 50-day moving average on January 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ICLR crossed bearishly below the 50-day moving average on February 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for ICLR moved below the 200-day moving average on February 26, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICLR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ICLR entered a downward trend on February 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.902) is normal, around the industry mean (12.488). P/E Ratio (14.857) is within average values for comparable stocks, (95.997). ICLR's Projected Growth (PEG Ratio) (4.789) is very high in comparison to the industry average of (1.731). ICLR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (1.091) is also within normal values, averaging (13.336).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ICLR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICLR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of clinical research and development services
Industry MedicalSpecialties
Advertisement